文章摘要
侯英娟,马亚玲,马亚峰,吕 涛,宋彦斌,郭 刚.普拉克索联合补肾活血通络胶囊治疗老年帕金森病的临床疗效及对血清5-HT、BDNF、S-100β水平的影响[J].,2020,(3):528-531
普拉克索联合补肾活血通络胶囊治疗老年帕金森病的临床疗效及对血清5-HT、BDNF、S-100β水平的影响
Clinical Efficacy of Pramipexole Combined with Bushen Huoxue Tongluo Capsule in the Treatment of Senile Parkinson's Disease and Its Effect on the Serum Levels of 5-HT, BDNF, S-100β
投稿时间:2019-04-10  修订日期:2019-04-30
DOI:10.13241/j.cnki.pmb.2020.03.027
中文关键词: 老年帕金森病  普拉克索  补肾活血通络胶囊  临床研究  5-羟色胺  脑源性神经营养因子  S-100β蛋白
英文关键词: Elderly Parkinson's disease  Bushen Huoxue Tongluo capsule  Pramipexole  5-hydroxytryptamine  Brain-derived neurotrophic factor  S-100β protein
基金项目:陕西省自然科学基金项目(20141016)
作者单位E-mail
侯英娟 陕西省榆林市第一医院 神经内科 陕西 榆林 718060 wxxxpkk@163.com 
马亚玲 陕西省榆林市第一医院 神经内科 陕西 榆林 718060  
马亚峰 延安大学第二附属医院 检验科 陕西 榆林 718000  
吕 涛 陕西省榆林市第一医院 神经内科 陕西 榆林 718060  
宋彦斌 陕西省榆林市第一医院 神经内科 陕西 榆林 718060  
郭 刚 西安市第四医院 神经内科 陕西 西安 710004  
摘要点击次数: 762
全文下载次数: 515
中文摘要:
      摘要 目的:分析普拉克索联合补肾活血通络胶囊治疗老年帕金森病的临床效果及对血清5-羟色胺(5-HT)、脑源性神经营养因子(BDNF)、S-100β水平的影响。方法:选择我院2014年12月~2016年12月收治的96例老年帕金森病患者,按随机数字表法分为对照组和研究组,每组48例。对照组采用普拉克索治疗,研究组基于对照组加以补肾活血通络胶囊治疗。观察并比较两组临床疗效指标统一帕金森病评分量表Ⅰ(unified parkinson's disease rating scale,UPDRS)Ⅰ、UPDRS Ⅱ、UPDRS Ⅲ、UPDRS Ⅳ、总 UPDRS,血清5-HT、BDNF、S-100β水平的变化及不良反应的发生情况。结果:治疗后,研究组总有效率为87.50%,显著高于对照组(64.58%,P<0.05)。两组治疗后的UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ、总UPDRS、血清S-100β水平均较治疗前显著下降,且研究组以上指标均明显低于对照组。两组治疗后的血清5-HT、BDNF水平均较治疗前明显上升,且研究组以上指标均明显高于对照组(P<0.05)。研究组不良反应发生率显著低于对照组(P<0.05)。结论:普拉克索联合补肾活血通络胶囊治疗治疗老年帕金森病的临床效果优于单用普拉克索,可能与其显著提高血清5-HT及BDNF表达并降低S-100β水平有关。
英文摘要:
      ABSTRACT Objective: To research the clinical efficacy of pramipexole combined with bushen huoxue tongluo capsule in the treatment of senile Parkinson's disease and analyze its effect on the serum levels of 5-hydroxytryptamine (5-HT), brain derived neurotrophic factor (BDNF), S-100. Methods: 96 cases of Parkinson's disease admitted from December 2014 to December 2016 were divided into the control group and the research group according to random number table method, with 48 cases in each group. The control group was treated with pramipexole, and the research group was treated with Bushen Huoxue Tongluo Capsule based on the control group. The clinical curative effect, changes of unified parkinson's disease rating scale(UPDRS) I, UPDRS II, UPDRS III, UPDRSI V, total UPDRS, serum levels of 5-HT, BDNF, S-100β, and adverse reactions occur between two groups was observed and compared. Results: After treatment, the total effective rate of study group was 87.50%, which was significantly higher than that of the control group (64.58%, P<0.05). the levels of UPDRSⅠ, UPDRSⅡ, UPDRSⅢ, UPDRSⅣ, total UPDRS, and serum S-100β in both groups after treatment were significantly lower than those before treatment. The above indexes in the research group are obviously lower than those in the control group.The levels of serum 5-HT and BDNF after treatment in both groups were significantly higher than those before treatment, and the above indexes in the research group were significantly higher than those in the control group (P<0.05). The adverse reaction rate in the research group was significantly lower than that in the control group (P<0.05). Conclusion: Pramipexole combined with Bushen Huoxue Tongluo capsule is superior to pramipexole alone in the treatment of senile Parkinson's disease, which may be related to significantly increasing the expression of serum level of 5-HT and BDNF and decreasing the level of S-100β.
查看全文   查看/发表评论  下载PDF阅读器
关闭